Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Could These Drugs Rain on the Obamacare Parade?

Obamacare's biggest fans just might be the health insurance industry. Several of the major insurers have enjoyed nice stock gains since the Oct. 1, 2013 start date for the health insurance exchanges established by the Affordable Care Act.

But could the health insurers' Obamacare parade get rained on soon? Some potentially dark clouds loom ahead – not from health reform itself, but instead from a new generation of medications.

You might expect insurers to be almost giddy these days. WellPoint (NYSE: ANTM  ) , for example, has seen its stock jump 23% since the exchanges launched. Humana (NYSE: HUM  ) experienced an even larger increase, with shares climbing 27% during the same period.

WellPoint stands out as the health insurer most closely linked with Obamacare. The company participated in the exchanges in every state where it operates. CEO Joe Swedish recently stated that WellPoint expects to add over 600,000 new members from public exchanges. The large insurer also experienced solid growth in its Medicaid business, in part due to the expansion of the program kicked off by health reform.

Likewise, Humana CEO Bruce Broussard thinks that his company will grow enrollment by as much as 500,000 members this year. In Humana's first-quarter earnings call, he noted that the company believes that its exchange enrollment is "skewed to a slightly younger population than the industry as a whole", a trend that helps the bottom line.

Chance of rain?
Both WellPoint and Humana, however, see a potential problem area: the cost of hepatitis C drugs. Joe Swedish said that WellPoint will spend around $100 million more on hep C medications in 2014 – twice what the company forked out last year.Bruce Broussard stated that hep C drugs would cost Humana $0.40 to $0.50 per share in added expense in 2014. 

On Tuesday, the health insurance industry's major trade group, America's Health Insurance Plans, or AHIP, singled out hepatitis C drug Sovaldi as a big reason those expenses are climbing. The drug, developed by Gilead Sciences (NASDAQ: GILD  ) , costs $84,000 per 12-week treatment.

Source: Gilead Sciences 

AHIP hit Gilead hard in an online statement, alleging that the drugmaker priced Sovaldi "at an astronomical level that is not sustainable for consumers, innovation, or society". Sovaldi gained regulatory approval in the U.S. in December and racked up over $2 billion in sales during its first full quarter on the market. That impressive figure seems likely to get even better if Gilead wins approval as expected later this year for an all-oral combo featuring Sovaldi and another of its drugs, ledipasvir.

Sunny forecasts
There are at least a couple of reasons to suspect that the health insurers' forecast is sunnier than AHIP lets on, though. First, competition is coming.

AbbVie (NYSE: ABBV  ) submitted its FDA application a month ago for a three-drug hep C combo. The pharmaceutical company scored positive results from late-stage clinical studies. Many observers expect AbbVie to be brought to market soon after Gilead's combo.

Merck (NYSE: MRK  ) also has a strong contender with its hep C regimen including two drugs, MK-5172 and MK-8742. It will take longer for Merck to compete, however. The drugmaker recently announced phase 2 study results and probably won't make it to market until 2016.

It's still too early to know how AbbVie and Merck might price their drugs. Insurers have reason to hope that the competition will help keep hep C costs from spiraling out of control.

The second positive for the health insurance industry when it comes to these drug costs comes from the flip side of the coin. Sure – Sovaldi costs a lot. But it and the other drugs on the way also could prevent the need for liver transplants in many hep C patients. A liver transplant costs around $600,000. Insurers should experience some reduced medical costs along the way from the new generation of hepatitis medications.

All parades eventually end, and the Obamacare parade won't be an exception. Health insurers thinking that hep C drug costs might rain on their parade, though, will probably find the weather to be better than feared.


Put some sunshine in your pocketbook
Give me five minutes and I'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks 1 stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.

Read/Post Comments (3) | Recommend This Article (4)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On May 25, 2014, at 8:54 PM, roger142 wrote:

    Oh, great, another article that does not give us the details I need to form an educated opinion. How about telling me exactly how much this Hepatitis drug cost in America? How about telling me how much it cost in other countries. Where is this drug manufactured?

    I know prescription drugs in America can easily cost us 1,000% to 9,000% more than people pay in other countries. I also know that it doesn't matter if a drug is made in America, or Mexico, or Turkey, or 45 other countries that have major pharmaceutical factories.

    I also know the department of fatherland security via the USPS will confiscate valid prescription drugs that American's order from Canada for 1/10th the price. Even though those drugs were made in the same factory as supplies my local drug store.

    Does any one remember back in 2002 when our news was actually showing old people who lived in the Southwest taking a bus tour into Mexican border towns just to be able to fill their prescriptions at 1/10th the price they paid on this side of the border?

    Does any one remember watching video of the Boarder Patrol confiscating a lot of those valid prescriptions?

  • Report this Comment On May 25, 2014, at 10:17 PM, lortep wrote:

    Despite the Congress being bought and paid for - by Big Pharme - if they go too far in ripping off the American People and Taxpayers - THEY CAN BE BROUGHT TO HEEL!

    The same drug they are charging American $80,000 - they are selling as low as $800 overseas.

    This has to fixed!

  • Report this Comment On May 26, 2014, at 8:06 PM, Carioca58 wrote:

    In response to the two comments above:

    According to today's Le Monde, Gilead's Hep C treatment costs between 60k-80k Euros in France.

    According to the Spanish newspaper El Pais, the price in Spain is in the same neighborhood, but the article published in Feb/2014 made me believe that the product is not available there yet.

    I tried to investigate the situation in Brazil, and it seems that Gilead's treatment is still not available to the general public.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2971221, ~/Articles/ArticleHandler.aspx, 9/2/2015 5:46:01 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Keith Speights

Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries.

Today's Market

updated Moments ago Sponsored by:
DOW 16,351.38 293.03 1.82%
S&P 500 1,948.86 35.01 1.83%
NASD 4,749.98 113.87 2.46%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/2/2015 4:00 PM
ABBV $60.98 Up +0.48 +0.79%
AbbVie Inc. CAPS Rating: ****
ANTM $140.47 Up +2.41 +1.75%
Anthem CAPS Rating: ****
GILD $104.27 Up +2.78 +2.74%
Gilead Sciences CAPS Rating: *****
HUM $181.70 Up +2.45 +1.37%
Humana, Inc. CAPS Rating: ****
MRK $52.98 Up +0.45 +0.86%
Merck & Co., Inc. CAPS Rating: ****